CT-388

1. CT-388 decreases body weight in humans (up to 22.7%).

   “CT-388 demonstrated clinically meaningful, statistically significant dose-dependent WL of up to 22.7% (W48)”

   Human trialoverweight/obesity without T2Dup to 24 mg once weekly48 weeksn = 467

   CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

2. CT-388 decreases body weight in humans (-18.9% (95% CI 14%-24%)).

   “CT-388 demonstrated placebo (pbo)-adjusted (adj) weight loss of 18.9% (95% CI 14%-24%)”

   Human trialobesity

   Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

3. CT-388 decreases body weight in humans (pbo-adj LSM of 7.4% [95% CI 4.9-9.8%]).

   “CT-388 and pbo treatment led to a % WL of 8.6% and 1.2% at 12 weeks, respectively (pbo-adj LSM of 7.4% [95% CI 4.9-9.8%]).”

   Human trialadults with obesity and T2Dsubcutaneous22 mg12 weeksn = 14

   Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

1. CT-388 improves normoglycemia in humans (73% vs 7.5%).

   “Among pts with prediabetes at BL, 73% of CT-388 24 mg achieved normoglycemia (vs 7.5% on Pbo).”

   Human trialprediabetes at baseline24 mg once weekly48 weeks

   CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

1. CT-388 decreases cT1 in humans (-52 ms (8-95 ms)).

   “reduction in LFC by 59% (31%-86%) and cT1 by 52 ms (8-95 ms).”

   Human trialobesityliver22 mg24 weeksn = 27

   Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on cT1

1. CT-388 decreases liver fat content in humans (-59% (95% CI 31%-86%)).

   “After 24 weeks, CT-388 pts had a pbo-adj least squares mean (LSM) (95% CI) reduction in LFC by 59% (31%-86%)”

   Human trialobesityliver22 mg24 weeksn = 27

   Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Liver fat content

1. CT-388 decreases HbA1c in humans (pbo-adj LSM reduction of 2.8% (95% CI: 2.1-3.6%)).

   “At 12 weeks, CT-388 and pbo treatment led to a reduction in HbA1c of 3.0% and 0.2%, respectively (pbo-adj least squares mean [LSM] of 2.8% [95% CI: 2.1-3.6%]).”

   Human trialadults with obesity and T2Dsubcutaneous22 mg12 weeksn = 14

   Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on HbA1c